GGrantIndex
← Leaderboards

Laura A Solt

Scripps Research Institute, The

$8,637,781
Attributed
$10,389,689
Total exposure
8
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.6M · FY201025
$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$10,389,689 · 8

By mechanism

R01$9,254,108 · 5
R21$531,300 · 1
R56$480,000 · 1
F32$124,281 · 1

Top collaborators

Others in their field

Top investigators on “Mouse Model

Research focus

Mouse ModelCellsMediatingReceptorLigandsIn VivoGenetic TranscriptionIn VitroResponseNuclear ReceptorsTranscription FactorProteinsPlayRegulationBaseTissuesMemberTranscription CoactivatorT-LymphocyteInflammatoryResponse ElementsSmall MoleculeGenetic ApproachBinding

Grant awards (25)

Ligand and transcriptional regulation of the nuclear receptor RORa on TH17 cell development and inflammation$618,072
R01 · FY2025 · DK · contact PI
Ligand-dependent regulation of the nuclear receptor REV-ERBa in TH17 cell development and inflammation$592,971
R01 · FY2025 · DK · contact PI
Ligand and transcriptional regulation of the nuclear receptor RORa on TH17 cell development and inflammation$618,072
R01 · FY2024 · DK · contact PI
Ligand-dependent regulation of the nuclear receptor REV-ERBa in TH17 cell development and inflammation$593,735
R01 · FY2024 · DK · contact PI
Ligand-dependent regulation of the nuclear receptor REV-ERBa in TH17 cell development and inflammation$592,971
R01 · FY2023 · DK · contact PI
Identification of cellular heme transport receptors that regulate T cell function$241,500
R21 · FY2023 · AI · contact PI
Identification of REV-ERB inverse agonists for cancer immunotherapy$614,469
R01 · FY2022 · CA · contact PI
Identification of cellular heme transport receptors that regulate T cell function$289,800
R21 · FY2022 · AI · contact PI
Identification of REV-ERB inverse agonists for cancer immunotherapy$392,550
R01 · FY2021 · CA · contact PI
Identification of REV-ERB inverse agonists for cancer immunotherapy$289,604
R01 · FY2021 · CA · contact PI
Identification of REV-ERB inverse agonists for cancer immunotherapy$643,014
R01 · FY2020 · CA · contact PI
Regulation of TH17 Cell Development and Function by the REV-ERBs$480,000
R01 · FY2020 · AI · contact PI
Identification of Chemical Probes for the Orphan Nuclear Receptor NR2F6$469,049
R01 · FY2020 · CA · contact PI
Identification of Chemical Probes for the Orphan Nuclear Receptor NR2F6$54,072
R01 · FY2020 · CA · contact PI
Identification of REV-ERB inverse agonists for cancer immunotherapy$547,678
R01 · FY2019 · CA · contact PI
Identification of Chemical Probes for the Orphan Nuclear Receptor NR2F6$529,984
R01 · FY2019 · CA · contact PI
Regulation of TH17 Cell Development and Function by the REV-ERBs$480,000
R01 · FY2019 · AI · contact PI
Identification of Chemical Probes for the Orphan Nuclear Receptor NR2F6$577,866
R01 · FY2018 · CA · contact PI
Regulation of TH17 Cell Development and Function by the REV-ERBs$480,000
R01 · FY2018 · AI · contact PI
Regulation of TH17 Cell Development and Function by the REV-ERBs$480,000
R01 · FY2017 · AI · contact PI
Regulation of TH17 Cell Development and Function by the REV-ERBs$200,001
R01 · FY2016 · AI · contact PI
Regulation of TH17 cell development and function by the REV-ERBs$480,000
R56 · FY2015 · AI · contact PI
Investigating the Mechanisms Regulating RORgamma Activity$19,865
F32 · FY2013 · DK · contact PI
Investigating the Mechanisms Regulating RORgamma Activity$53,942
F32 · FY2012 · DK · contact PI
Investigating the Mechanisms Regulating RORgamma Activity$50,474
F32 · FY2010 · DK · contact PI